Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles

Mingfeng Shao,1 Wenfang Yang,2 Guangying Han1 1Department of Cardiology, Linyi People’s Hospital, Linyi, Shandong, People’s Republic of China; 2Department of Internal Medicine, Linyi Hot Spring Hospital of Shandong Coal Mine, Linyi, Shandong,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shao M, Yang W, Han G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Cardiovascular diseases (CVDs) schisandrin B matrix-metalloproteinase lipid nanoparticles Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/72a5c4da97394845896de1954785c342
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:72a5c4da97394845896de1954785c342
record_format	dspace
spelling	oai:doaj.org-article:72a5c4da97394845896de1954785c3422021-12-02T05:09:41ZProtective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles1178-2013https://doaj.org/article/72a5c4da97394845896de1954785c3422017-09-01T00:00:00Zhttps://www.dovepress.com/protective-effects-on-myocardial-infarction-model-delivery-of-schisand-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Mingfeng Shao,1 Wenfang Yang,2 Guangying Han1 1Department of Cardiology, Linyi People’s Hospital, Linyi, Shandong, People’s Republic of China; 2Department of Internal Medicine, Linyi Hot Spring Hospital of Shandong Coal Mine, Linyi, Shandong, People’s Republic of China Purpose: Schisandrin B (Sch B) is clinically applied for the treatment of hepatitis and ischemic disease. However, its clinical efficacy is limited due to the poor solubility and low bioavailability. This study aimed to develop matrix metalloproteinase (MMP)-sensitive peptide-modified, polyethylene glycol (PEG)-modified (PEGylated) solid lipid nanoparticles (SLNs) for loading Sch B (MMP-Sch B SLNs), and to evaluate the therapeutic effect in the myocardial infarction model.Methods: PEG lipid and MMP-targeting peptide conjugate were synthesized. MMP-Sch B SLNs were prepared by solvent displacement technique. The physicochemical properties and pharmacokinetics of SLNs were investigated. In vivo effects on infarct size was evaluated in rats.Results: The successful synthesis of lipid-peptide conjugate was confirmed. MMP-Sch B SLNs had a particle size of 130 nm, a zeta potential of 18.3 mV, and a sustained-release behavior. Higher heart drug concentration and longer blood circulation times were achieved by Sch B loaded SLNs than the drug solution according to the pharmacokinetic and biodistribution results. The best therapeutic efficacy was exhibited by MMP-Sch B SLNs by reducing the infarction size to the greatest extent.Conclusion: The modified SLNs may be a good choice for delivery of Sch B for the treatment of myocardial infarction. Keywords: cardiovascular diseases, CVDs, schisandrin B, matrix metalloproteinase, lipid nanoparticlesShao MYang WHan GDove Medical PressarticleCardiovascular diseases (CVDs)schisandrin Bmatrix-metalloproteinaselipid nanoparticlesMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 7121-7130 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cardiovascular diseases (CVDs) schisandrin B matrix-metalloproteinase lipid nanoparticles Medicine (General) R5-920
spellingShingle	Cardiovascular diseases (CVDs) schisandrin B matrix-metalloproteinase lipid nanoparticles Medicine (General) R5-920 Shao M Yang W Han G Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles
description	Mingfeng Shao,1 Wenfang Yang,2 Guangying Han1 1Department of Cardiology, Linyi People’s Hospital, Linyi, Shandong, People’s Republic of China; 2Department of Internal Medicine, Linyi Hot Spring Hospital of Shandong Coal Mine, Linyi, Shandong, People’s Republic of China Purpose: Schisandrin B (Sch B) is clinically applied for the treatment of hepatitis and ischemic disease. However, its clinical efficacy is limited due to the poor solubility and low bioavailability. This study aimed to develop matrix metalloproteinase (MMP)-sensitive peptide-modified, polyethylene glycol (PEG)-modified (PEGylated) solid lipid nanoparticles (SLNs) for loading Sch B (MMP-Sch B SLNs), and to evaluate the therapeutic effect in the myocardial infarction model.Methods: PEG lipid and MMP-targeting peptide conjugate were synthesized. MMP-Sch B SLNs were prepared by solvent displacement technique. The physicochemical properties and pharmacokinetics of SLNs were investigated. In vivo effects on infarct size was evaluated in rats.Results: The successful synthesis of lipid-peptide conjugate was confirmed. MMP-Sch B SLNs had a particle size of 130 nm, a zeta potential of 18.3 mV, and a sustained-release behavior. Higher heart drug concentration and longer blood circulation times were achieved by Sch B loaded SLNs than the drug solution according to the pharmacokinetic and biodistribution results. The best therapeutic efficacy was exhibited by MMP-Sch B SLNs by reducing the infarction size to the greatest extent.Conclusion: The modified SLNs may be a good choice for delivery of Sch B for the treatment of myocardial infarction. Keywords: cardiovascular diseases, CVDs, schisandrin B, matrix metalloproteinase, lipid nanoparticles
format	article
author	Shao M Yang W Han G
author_facet	Shao M Yang W Han G
author_sort	Shao M
title	Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles
title_short	Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles
title_full	Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles
title_fullStr	Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles
title_full_unstemmed	Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles
title_sort	protective effects on myocardial infarction model: delivery of schisandrin b using matrix metalloproteinase-sensitive peptide-modified, pegylated lipid nanoparticles
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/72a5c4da97394845896de1954785c342
work_keys_str_mv	AT shaom protectiveeffectsonmyocardialinfarctionmodeldeliveryofschisandrinbusingmatrixmetalloproteinasesensitivepeptidemodifiedpegylatedlipidnanoparticles AT yangw protectiveeffectsonmyocardialinfarctionmodeldeliveryofschisandrinbusingmatrixmetalloproteinasesensitivepeptidemodifiedpegylatedlipidnanoparticles AT hang protectiveeffectsonmyocardialinfarctionmodeldeliveryofschisandrinbusingmatrixmetalloproteinasesensitivepeptidemodifiedpegylatedlipidnanoparticles
_version_	1718400536478220288

Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles

Ejemplares similares